RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is developing the next generation of immuno-oncology therapeutics based on its novel RNAi therapeutic platform including self-delivering RNAi (sd-rxRNA®) compounds.
Discover the most promising early-stage companies in life sciences, scouted by BioPharmaTrend. Follow company news and important business events.
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is developing the next generation of immuno-oncology therapeutics based on its novel RNAi therapeutic platform including self-delivering RNAi (sd-rxRNA®) compounds.